
Publication|Articles|October 10, 2025
- October 2025
- Volume 91
- Issue 10
FDA Approvals for September 2025
Author(s)PT Staff
Key Takeaways
- Recent FDA approvals highlight advancements in oncology, focusing on therapies targeting specific genetic mutations for personalized treatment.
- Expedited review processes by the FDA have enabled quicker access to innovative cancer treatments, improving patient outcomes.
Explore recent FDA-approved drugs from September 2025.
Advertisement
FDA Approvals
Articles in this issue
4 months ago
OTC Case Studies: Dry EyeNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























